Vivo Capital’s Legend Biotech LEGN Stock Holding History

Vivo Capital’s Portfolio LEGN Stock Details LEGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-244,375	Closed	-$11.8M	–	49
2023 Q1	$11.8M	Hold	244,375	–	–	0.82%	19
2022 Q4	$12.2M	Hold	244,375	–	–	1.4%	19
2022 Q3	$9.97M	Hold	244,375	–	–	1.1%	24
2022 Q2	$13.4M	Hold	244,375	–	–	1.35%	20
2022 Q1	$8.88M	Hold	244,375	–	–	0.61%	31
2021 Q4	$11.4M	Sell	244,375 -244,376	-50%	-$12.4M	0.69%	32
2021 Q3	$24.7M	Sell	488,751 -467,951	-49%	-$19.5M	1.11%	22
2021 Q2	$39.3M	Sell	956,702 -1,798,305	-65%	-$61.1M	1.7%	13
2021 Q1	$80M	Hold	2,755,007	–	–	2.81%	11
2020 Q4	$77.6M	Sell	2,755,007 -575,262	-17%	-$16.6M	3.46%	9
2020 Q3	$103M	Sell	3,330,269 -224,738	-6%	-$7.57M	5.94%	5
2020 Q2	$151M	Buy	+3,555,007	New	+$139M	10.85%	2

Other funds holding LEGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vivo Capital's LEGN Position: Q2 2023 in Review

Vivo Capital sold out of Legend Biotech (LEGN) in Q2 2023, closing a stake of 244,375 shares — an estimated $11.8M sold.

Vivo Capital first reported a position in LEGN in Q2 2020 and held it in 12 quarters. The position peaked at $151M in Q2 2020. 194 funds tracked by Wall St. Rank hold LEGN as of Q2 2023.

Vivo Capital reported no remaining Legend Biotech position as of Q2 2023 after selling out during the quarter.
Vivo Capital sold 244,375 Legend Biotech shares in Q2 2023, an estimated $11.8M.
Vivo Capital first reported a position in Legend Biotech in Q2 2020 and held it in 12 quarters.
Vivo Capital's Legend Biotech position peaked at $151M in Q2 2020.
194 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2023.

Based on Vivo Capital's 13F filing for Q2 2023, filed 14 Aug 2023.